A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

Medicare Part D spent a total of $4.6 billion on Ozempic in 2022, based on the most recent data we have from the Centers for Medicare & Medicaid Services. This spending covered 780,253 ...

Ozempic, the blockbuster diabetes treatment from Novo Nordisk, could be next in line to face price negotiations between manufacturers and Medicare. The Biden administration released the first 10 ...

Medicare shelled out $5.7 billion on Ozempic and other similar diabetes drugs in 2022, up from $57 million in 2018, according to a new KFF analysis.

Medicare shelled out $5.7 billion on Ozempic and other similar diabetes drugs in 2022, up from $57 million in 2018, according to a new KFF analysis.

Medicare covers Ozempic for Type 2 diabetes Medicare prescription drug plans might cover Ozempic, but only to treat diabetes. In 2021, Medicare spent over $2.6 billion to cover Ozempic ...

A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic, were linked to a 33% lower risk of ...